464 related articles for article (PubMed ID: 20458041)
21. Monoclonal antibody therapy of chronic lymphocytic leukaemia.
Cheson BD
Best Pract Res Clin Haematol; 2010 Mar; 23(1):133-43. PubMed ID: 20620977
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.
Church AK; VanDerMeid KR; Baig NA; Baran AM; Witzig TE; Nowakowski GS; Zent CS
Clin Exp Immunol; 2016 Jan; 183(1):90-101. PubMed ID: 26307241
[TBL] [Abstract][Full Text] [Related]
23. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.
Maloney DG
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S19-26. PubMed ID: 15786022
[TBL] [Abstract][Full Text] [Related]
24. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
Robak T
Future Oncol; 2013 Jan; 9(1):69-91. PubMed ID: 23252565
[TBL] [Abstract][Full Text] [Related]
25. BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.
Nishida M; Uematsu N; Kobayashi H; Matsunaga Y; Ishida S; Takata M; Niwa O; Padlan EA; Newman R
Int J Oncol; 2011 Feb; 38(2):335-44. PubMed ID: 21152859
[TBL] [Abstract][Full Text] [Related]
26. Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.
Kobayashi H; Matsunaga Y; Uchiyama Y; Nagura K; Komatsu Y
Cancer Med; 2013 Apr; 2(2):130-43. PubMed ID: 23634281
[TBL] [Abstract][Full Text] [Related]
27. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.
Korycka-Wołowiec A; Wołowiec D; Robak T
Expert Opin Drug Saf; 2015; 14(12):1945-59. PubMed ID: 26566719
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
[TBL] [Abstract][Full Text] [Related]
29. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.
Jain P; O'Brien S
Expert Opin Biol Ther; 2013 Feb; 13(2):169-82. PubMed ID: 23256681
[TBL] [Abstract][Full Text] [Related]
30. The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.
Smolewski P; Robak T
Expert Opin Drug Discov; 2015 Jul; 10(7):791-808. PubMed ID: 26083358
[TBL] [Abstract][Full Text] [Related]
31. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
[TBL] [Abstract][Full Text] [Related]
32. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Goede V; Klein C; Stilgenbauer S
Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
34. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders.
Robak T
Curr Opin Mol Ther; 2008 Jun; 10(3):294-309. PubMed ID: 18535937
[TBL] [Abstract][Full Text] [Related]
35. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
36. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.
Castillo J; Milani C; Mendez-Allwood D
Expert Opin Investig Drugs; 2009 Apr; 18(4):491-500. PubMed ID: 19335277
[TBL] [Abstract][Full Text] [Related]
37. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
[TBL] [Abstract][Full Text] [Related]
38. Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions.
Reagan PM; Friedberg JW
Oncology (Williston Park); 2017 May; 31(5):402-11. PubMed ID: 28516439
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression.
Shimada K; Tomita A; Saito S; Kiyoi H
Br J Haematol; 2014 Aug; 166(3):455-7. PubMed ID: 24673649
[No Abstract] [Full Text] [Related]
40. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
